Global Molecular Diagnosis of Tumors Market Growth (Status and Outlook) 2023-2029

Global Molecular Diagnosis of Tumors Market Growth (Status and Outlook) 2023-2029

The global Molecular Diagnosis of Tumors market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.

United States market for Molecular Diagnosis of Tumors is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

China market for Molecular Diagnosis of Tumors is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Europe market for Molecular Diagnosis of Tumors is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Global key Molecular Diagnosis of Tumors players cover Abbott Laboratories, Roche Holding, Thermo Fisher Scientific, Danaher Corporation, Veracyte, TBG Diagnostics, Agilient Technologies, Illumina and Genecast, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.

LPI (LP Information)' newest research report, the “Molecular Diagnosis of Tumors Industry Forecast” looks at past sales and reviews total world Molecular Diagnosis of Tumors sales in 2022, providing a comprehensive analysis by region and market sector of projected Molecular Diagnosis of Tumors sales for 2023 through 2029. With Molecular Diagnosis of Tumors sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Molecular Diagnosis of Tumors industry.

This Insight Report provides a comprehensive analysis of the global Molecular Diagnosis of Tumors landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Molecular Diagnosis of Tumors portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Molecular Diagnosis of Tumors market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Molecular Diagnosis of Tumors and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Molecular Diagnosis of Tumors.

This report presents a comprehensive overview, market shares, and growth opportunities of Molecular Diagnosis of Tumors market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
NGS-Based
PCR-Based

Segmentation by application
Hospitals
Diagnostic Centers
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Abbott Laboratories
Roche Holding
Thermo Fisher Scientific
Danaher Corporation
Veracyte
TBG Diagnostics
Agilient Technologies
Illumina
Genecast
Burning Rock Biotech

Please note: The report will take approximately 2 business days to prepare and deliver.